{"nctId":"NCT01078675","briefTitle":"An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia","startDateStruct":{"date":"2010-02"},"conditions":["Familial Hypercholesterolaemia"],"count":315,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: rosuvastatin calcium"]}],"interventions":[{"name":"rosuvastatin calcium","otherNames":["Crestor"]},{"name":"rosuvastatin calcium","otherNames":["Crestor"]},{"name":"rosuvastatin calcium","otherNames":["Crestor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* children and adolescents (aged 6 to less than 18 years) with Familial Hypercholesterolaemia\n* Patients aged between 6 and less than 10 years of age must not be taking a statin medicine\n\nExclusion Criteria:\n\n* History of muscle or sensitivity reactions to any statin medicines\n* Current active liver disease or dysfunction (except a confirmed diagnosis of Gilbert's disease)","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in LDL-C","description":"Negative values represent a decrease and positive values represent an increase. In total, 198 patients were treated. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.86","spread":"14.392"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.67","spread":"14.896"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.88","spread":"18.222"}]}]}]},{"type":"PRIMARY","title":"Sexual Maturation by Tanner Staging at Baseline","description":"Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Single Dose PK - Cmax","description":"Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5717","spread":"3.22350"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C, TC, TG, Non-HDL-C, LDL-C/HDL-C, TC/HDL-C, Non HDL C/HDL-C, ApoB, ApoA-1, and ApoB/ApoA-1","description":"One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.67","spread":"17.445"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.35","spread":"16.725"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.73","spread":"19.996"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.60","spread":"11.433"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.91","spread":"12.050"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.03","spread":"14.530"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.95","spread":"34.482"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.85","spread":"37.530"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"37.682"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.35","spread":"13.368"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.66","spread":"14.235"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.40","spread":"17.555"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.66","spread":"17.381"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.63","spread":"17.082"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.95","spread":"20.126"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.77","spread":"14.874"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.54","spread":"14.474"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.39","spread":"17.079"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.05","spread":"41.765"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.50","spread":"40.633"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.12","spread":"40.585"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.98","spread":"17.369"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.71","spread":"16.731"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.74","spread":"19.896"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.77","spread":"14.680"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.41","spread":"13.747"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":"15.027"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.29","spread":"12.456"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.65","spread":"12.424"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.72","spread":"15.710"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.30","spread":"15.524"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.66","spread":"13.920"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.94","spread":"18.743"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"512.57","spread":"4724.249"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.96","spread":"226.954"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.36","spread":"565.444"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Max and Mean Carotid Intima and Media Wall Thickness (cIMT)","description":"One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00626","spread":"0.073446"},{"groupId":"OG001","value":"0.01707","spread":"0.056223"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00189","spread":"0.060864"},{"groupId":"OG001","value":"0.01202","spread":"0.049102"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00282","spread":"0.041186"},{"groupId":"OG001","value":"0.01564","spread":"0.032052"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01056","spread":"0.040762"},{"groupId":"OG001","value":"0.02779","spread":"0.031004"}]}]}]},{"type":"SECONDARY","title":"Adverse Events","description":"Number of participants with Various Categories of AE's. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"172","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Duration of Exposure","description":"Total duration of exposure was calculated as \\[last dose date of rosuva - first dose date of rosuva + 1 day\\]. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"703.5","spread":"97.25"}]}]}]},{"type":"PRIMARY","title":"Percent Change From Baseline in Height","description":"One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.20","spread":"2.023"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.91","spread":"3.968"}]}]}]},{"type":"PRIMARY","title":"Sexual Maturation by Tanner Staging at Month 12","description":"Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]},{"type":"PRIMARY","title":"Sexual Maturation by Tanner Staging at Month 24","description":"Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Single Dose PK - Tmax","description":"Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.664","spread":"1.8851"}]}]}]},{"type":"PRIMARY","title":"Single Dose PK - AUC(0-24)","description":"Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.675","spread":"26.6417"}]}]}]},{"type":"SECONDARY","title":"Overal Treatment Adherence","description":"Overall adherence rate was calculated as the weighted mean of adherence rates of all consecutive visits after baseline, in which the adherence rate between 2 consecutive visits was a percentage of the number of rosuvastatin taken divided by duration of exposure. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.6","spread":"12.25"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":197},"commonTop":["Nasopharyngitis","Headache","Influenza","Vomiting","Nausea"]}}}